Octreotide and Insulin Aspart Interaction

Understanding the Octreotide and Insulin Aspart Interaction

FDA-approved prescribing information for these two drugs flags their combination as a moderate-severity interaction. Octreotide belongs to the Somatostatin Analog class and Insulin Aspart belongs to the Rapid-Acting Insulin class - two categories that can collide when co-prescribed. The mechanism described in FDA labeling is: Octreotide can change how your body handles sugar and may increase the blood-sugar-lowering effects of insulin. Severity tiers matter: major flags generally advise avoidance, moderate flags often require monitoring or dose adjustment, and minor flags may only call for awareness.

Context around a specific patient determines real-world impact. Octreotide has 14 total documented interactions on file in this dataset, and Insulin Aspart has 11. Each additional medication compounds the interaction surface, which is why pharmacists run full-profile checks rather than evaluating one pair at a time. FDA-derived guidance for this pair is: Be sure to monitor your blood sugar frequently while using these drugs together. Timing of doses, renal and hepatic function, age, and other concurrent prescriptions all shape whether a labeled interaction matters clinically.

An interaction flag is not a verdict. A large share of labeled interactions are managed routinely in clinical practice, the fix may be as simple as spacing doses or adding a monitoring test. Others require the prescriber to choose a different medication entirely. This page surfaces FDA-sourced labeling and openFDA data for educational purposes only; it is not medical advice and cannot account for your full clinical picture. Never start, stop, or adjust either Octreotide or Insulin Aspart based on a web page, speak with your prescriber or pharmacist before making any change.